Definium Therapeutics, Inc.
DFTX
Pozycja w akcjach
#3577
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Cena akcji
$35.52
Kapitalizacja rynkowa
$4.77B
Zmiana (1 dzień)
1.24%
Zmiana (1 rok)
181.04%
Kraj
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategoria
Healthcare
Historia ceny akcji dla Definium Therapeutics, Inc. (DFTX)
Najwyższa cena zamknięcia: $35.12 dnia 2026-10-01
Najniższa cena zamknięcia: $4.81 dnia 2016-11-01
Najniższa cena zamknięcia: $4.81 dnia 2016-11-01
Historia cen akcji firmy Definium Therapeutics, Inc. od 2016 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 98.59% |
| 2025 | 74.98% |
| 2024 | 107.98% |
| 2023 | 34.70% |
| 2022 | -89.90% |
| 2021 | -40.72% |
| 2020 | 7,946.66% |
| 2019 | -31.09% |
| 2018 | -81.58% |
| 2017 | -37.50% |
| 2016 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $137.75 | -3.72% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
